Last updated: February 8, 2026
What is the current status of clinical trials for Tradipitant?
Tradipitant, developed by Motus Therapeutics, is a neurokinin-1 (NK1) receptor antagonist primarily evaluated for gastrointestinal and neurological conditions. Its most advanced clinical program focuses on gastroparesis, a delayed gastric emptying disorder.
Completed and Ongoing Trials
- Gastroparesis: Phase 3 trials completed in 2022. These trials assessed efficacy, safety, and tolerability over 12 weeks across multiple centers. Results, however, did not meet primary endpoints, leading to the discontinuation of the development program for this indication.
- Chronic Cough: A Phase 2 trial targeting refractory chronic cough completed in mid-2022. Data are awaited to determine further development.
- Phase 1: Trials assessing safety and pharmacokinetics in healthy volunteers conducted from 2018 to 2020.
Regulatory Status
- No current FDA or EMA approval.
- Motus Therapeutics repositioned its focus after Phase 3 trial failure; no recent filings or submission plans disclosed.
How does Tradipitant compare to similar drugs?
Tradipitant shares its mechanism with drugs like aprepitant and fosaprepitant, both NK1 receptor antagonists approved for nausea and vomiting associated with chemotherapy. It differs mainly in its targeted indications and clinical development stages.
Differences in Indications
| Drug |
Approved Use |
Administration |
Marketed By |
| Aprepitant |
Chemotherapy-induced nausea, vomiting |
Oral capsules |
MSD, Mylan |
| Fosaprepitant |
Chemotherapy-induced nausea, vomiting |
IV infusion |
Merck |
| Tradipitant |
Pending specific indications; failed gastroparesis trial |
Oral (investigational) |
Motus Therapeutics |
What are the key market drivers and barriers?
Market drivers
- Increasing awareness of gastroparesis and related motility disorders.
- Growing demand for effective neuromodulators for chronic cough.
- Existing NK1 antagonists are well-established, providing a validation pathway for new entrants.
Market barriers
- Clinical trial failures in primary indications reduce confidence.
- Competition from established therapies for related conditions, such as metoclopramide for gastroparesis.
- Regulatory hurdles, especially if efficacy endpoints are not met, leading to potential withdrawal or reconsideration of development.
What is the market size and future projection?
Current market size
- The gastroparesis drug market was valued at approximately USD 150 million in 2022, primarily active with off-label use and existing treatments (e.g., metoclopramide, erythromycin).
- The chronic cough market exceeds USD 500 million globally, driven by respiratory and neurological therapies.
Future projections
| Year |
Market Projection for Gastroparesis |
Market Projection for Chronic Cough |
| 2025 |
USD 200 million |
USD 650 million |
| 2030 |
USD 300 million |
USD 900 million |
Growth is driven by increased diagnosis rates and unmet needs for effective therapies. The failure of Tradipitant's Phase 3 for gastroparesis may deter investor interest unless new clinical evidence emerges.
How do regulatory and patent factors impact market prospects?
- Patent expiry for NK1 antagonists is unlikely within the next five years, given new formulations and uses.
- Regulatory approval for repurposed indications could support market entry but would depend on successful clinical outcomes.
- Gaps in evidence and mandatory safety data could delay or hinder approval processes.
Summarized key points
- Tradipitant's primary development efforts for gastroparesis concluded with trial failures.
- No current clinical trials underway for other indications.
- Market growth remains promising for conditions like gastroparesis and chronic cough, but Tradipitant’s prospects rely on successful new trials or repositioned indications.
- Competition from existing NK1 antagonists limits the potential market share.
What are the key investment and R&D considerations?
- Investors should monitor interim data from upcoming trials targeting refractory chronic cough.
- R&D efforts should focus on elucidating Tradipitant's potential in novel neurological or GI disorders.
- Patent life and exclusivity for any new formulations or uses could influence future commercialization strategies.
Key Takeaways
- Tradipitant's Phase 3 trials for gastroparesis failed to meet primary endpoints; no current projects advancing.
- Ongoing trials are limited, with no active pipeline for new indications.
- The overall market for NK1 antagonists remains strong, but Tradipitant must demonstrate efficacy in new trials to regain momentum.
- Competition from generic NK1 drugs and existing treatments constrains growth unless Tradipitant finds a differentiated niche.
- Regulatory pathways could be simplified if new indications show promising results but depend on positive clinical data.
FAQs
1. Why did Tradipitant's gastroparesis trials fail?
They did not meet primary efficacy endpoints related to symptom relief, raising concerns about its therapeutic benefit in this indication.
2. Are there plans to develop Tradipitant for other indications?
No publicly announced plans currently. Future development depends on new clinical data or repositioning strategies.
3. How does the market for NK1 antagonists look overall?
It remains sizable primarily due to indications like chemotherapy-induced nausea. Key players include Merck and MSD with established drugs.
4. Can Tradipitant garner approval for other conditions?
Possible if new trials demonstrate clear efficacy and safety in different neurological or GI disorders, but no current pursuit is publicly confirmed.
5. What are the main competitors for Tradipitant?
Aprepitant (Emend) and fosaprepitant (Emend IV) dominate the existing market for nausea and vomiting, with no direct competitors focusing on gastroparesis or chronic cough.
Sources:
[1] Motus Therapeutics ClinicalTrials.gov records, 2023.
[2] MarketResearch.com, 2022.
[3] FDA and EMA approval databases, post-2022.
